Terms: = Liver cancer AND GNA11, GNA-11, 2767, ENSG00000088256 AND Treatment
15 results:
1. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
2. Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.
Mariani P; Bidard FC; Rampanou A; Houy A; Servois V; Ramtohul T; Pierron G; Chevrier M; Renouf B; Lantz O; Gardrat S; Vincent-Salomon A; Roman-Roman S; Rodrigues M; Piperno-Neumann S; Cassoux N; Stern MH; Renault S
Ann Surg; 2023 Oct; 278(4):e827-e834. PubMed ID: 36847256
[TBL] [Abstract] [Full Text] [Related]
3. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract] [Full Text] [Related]
4. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract] [Full Text] [Related]
5. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract] [Full Text] [Related]
6. Uveal melanoma.
Jager MJ; Shields CL; Cebulla CM; Abdel-Rahman MH; Grossniklaus HE; Stern MH; Carvajal RD; Belfort RN; Jia R; Shields JA; Damato BE
Nat Rev Dis Primers; 2020 Apr; 6(1):24. PubMed ID: 32273508
[TBL] [Abstract] [Full Text] [Related]
7. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract] [Full Text] [Related]
8. Uveal melanoma: physiopathology and new in situ-specific therapies.
Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
[TBL] [Abstract] [Full Text] [Related]
9. The biology of uveal melanoma.
Amaro A; Gangemi R; Piaggio F; Angelini G; Barisione G; Ferrini S; Pfeffer U
Cancer Metastasis Rev; 2017 Mar; 36(1):109-140. PubMed ID: 28229253
[TBL] [Abstract] [Full Text] [Related]
10. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract] [Full Text] [Related]
11. treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract] [Full Text] [Related]
12. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract] [Full Text] [Related]
13. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection.
García-Niño WR; Zazueta C
Pharmacol Res; 2015 Jul; 97():84-103. PubMed ID: 25941011
[TBL] [Abstract] [Full Text] [Related]
14. [Uveal melanoma: current insights into clinical relevance of genetic testing].
Metz CH; Lohmann D; Zeschnigk M; Bornfeld N
Klin Monbl Augenheilkd; 2013 Jul; 230(7):686-91. PubMed ID: 23877823
[TBL] [Abstract] [Full Text] [Related]
15. Proportion of gynecologic cancer patients using complementary and alternative medicine.
Supoken A; Chaisrisawatsuk T; Chumworathayi B
Asian Pac J Cancer Prev; 2009; 10(5):779-82. PubMed ID: 20104968
[TBL] [Abstract] [Full Text] [Related]
